MAPT and Alzheimer disease: Previous work has suggested that this effect may only pertain to preclinical AD, wherein women showed faster rates of cognitive decline at similar (high) levels of tau pathology compared with men.53 The association between baseline tau PET and cognitive change over time did not differ by APOE genotype.